- Home
- SAIA vs JAZZ Comparison
SAIA vs JAZZ Comparison
Compare SAIA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAIA | JAZZ |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.4B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SAIA | JAZZ |
|---|---|---|
| Price | $458.11 | $239.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 14 |
| Target Price | ★ $391.06 | $217.57 |
| AVG Volume (30 Days) | 378.7K | ★ 843.6K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.86 | ★ 4.43 |
| Revenue | ★ $3,234,286,000.00 | $1,618,693,000.00 |
| Revenue This Year | $7.29 | $6.22 |
| Revenue Next Year | $9.08 | $7.68 |
| P/E Ratio | $245.72 | ★ $54.00 |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $248.37 | $105.00 |
| 52 Week High | $471.73 | $242.18 |
Technical Indicators
Market Signals| Indicator | SAIA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 76.29 |
| Support Level | $324.03 | $128.87 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 19.70 | 6.17 |
| MACD | -0.59 | 1.13 |
| Stochastic Oscillator | 78.51 | 93.17 |
Price Performance
Historical ComparisonAbout SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.